At baseline, in all ACS patients, endothelial dysfunction parameters registered an increased incidence as follows: Low value of flow-mediated dilation (FMD) < 4.5%—in NSTE-ACS Omega-3 PUFAs (53%) and NSTE-ACS (50.87%) and also in STE-ACS Omega-3 PUFAs (52.56%) and STE-ACS (51.26%); high level of von Willebrand factor activity (vWf activity) > 169.7%—in NSTE-ACS Omega-3 PUFAs (55.12%) and NSTE-ACS (52.61%) and also in STE-ACS Omega-3 PUFAs (54.61%) and STE-ACS (54.51%). Here, VWF is linked to endothelial dysfunction.